The new player of the year award is granted to the most active and vibrant VC fund that’s been in the market for no longer than a year. The panel considers the number of deals closed within the said period and the total amount of funds invested . The nomination included such VC funds as Caspian VC, GVA LaunchGurus Fund, Edison VC, Kinetik.
RBV Capital is a VC fund managed by RusBio Ventures. The fund was established in December 2014 by RVC and R-Pharm to invest in innovative biomedical projects. RBV Capital has over RUB 2 billion under management and the intention is to invest at least half of this money in Russian projects. The fund is the first independent investment partnership in Russia. The Fund’s Investment Committee and the Science and Technology Council embrace famous experts, including representatives of R-Pharm, Pfizer and other industry leaders. In the first year the fund hired a team of highly skilled professionals and closed two investment deals worth a total of RUB 300 million, each in cooperation with famous foreign investors specializing in the industry.
The award has a total of 12 nominations: Newcomer of the Year, Person of the Year, General Partner of the Year, Seed Investor of the Year, Corporate Fund of the Year, Non-IT Venture of the year, Strategy Investor of the Year, Deal of the Year, Exit of the Year, Fund of the Year, Venture Team of the Year, Angel Investor of the Year.
The winners in each nomination were selected by a panel comprising authoritative affiliated Russian experts and venture capitalists such as RVC CEO Igor Agamirzyan, RVC Investment Department Director Ruslan Akhmetov, the founder of banki.ru Filipp Ilyin-Adaev, Sberbank Strategic Business Development Director Igor Karpovich, Arbat Capital Managing Director Aleksey Golubovich, former Deputy Minister of Transport, business angel Anna Belova, EY Partner Vadim Ilyin, McKinsey Partner Irina Shvakman, Director of the PricewaterhouseCoopers Center for Technology and Innovation Anton Abashkin, Investor Relations Director of RUSNANO Alexander Pankov, Baring Vostok Capital Partners Senior Partner Elena Ivashentseva.
For more information visit the Awards site: http://ventureawards.ru/.
RVC OJSC is a state fund of funds, development institution of the Russian Federation, and one of the key tools of the state in creating national innovation system. The authorized capital of RVC is more than 30 billion rubles. RVC's capital is owned in full by the Russian Federation represented by the Federal Agency for State Property Management of the Russian Federation (Rosimushestvo). The total number of funds formed by RVC has reached 22 with the aggregate size of RUB 30.3 bn. The share of RVC is RUB 19.3 bn. The number of innovative companies approved for investment by RVC funds reached 184. The total amount of invested assets reached 17 billion rubles. Since 2015, RVC OJSC has been defined as a project office for implementation of the National Technology Initiative (NTI) — the long-term strategy of the country's technological development, aimed at formation of new global markets by 2035.
R-Pharm CJSC is a Russian high-tech pharmaceutical company, which was founded in 2001. The company specializes in developing, testing, manufacturing and marketing a broad range of pharmaceutical products intended primarily for in-patient hospital care and specialized care. In 2002 the company began supplying Russian clinics and research institutes and one year later was able to set up a chain of regional branches. In 2007 the company was selected as one of the suppliers for the state program of additional pharmaceutical supplies. In 2009 R-Pharm began licensed manufacture of a number of foreign medications in Russia. Currently, R-Pharm is building a high-tech manufacturing complex in Yaroslavl and plans to buy shares in Novosibkhimpharm. The company is also fixing to launch production of solid pharmaceutical products Ortat in Kostroma region. In January 2011 R-Pharm founded the research company R-Pharm Overseas Inc. in San-Diego, USA. In 2012 the company began construction of a manufacturing facility for making active pharmaceutical ingredients of chemical nature in Rostov. The project was run through the subsidiary Pharmaslavl. In 2013 the company set up a subsidiary in Turkey. In 2014 it purchased a manufacturing facility from Pfizer in Germany and launched operations in the USA and Japan.